CompletedNot Applicable

Moderate Intensity Training in Patients With Truncating Genetic Variants in TTN.

Denmark14 participantsStarted 2022-02-14

Plain-language summary

The aim is to investigate the effect of an 8-week moderate-intensity exercise program on aerobic fitness and cardiac contractility in patients with truncations of the sarcomeric protein titin.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years
✓. Mutations in the TTN gene leading to truncating variants in cardiac expressed exons of titin.
✓. A clinical diagnosis of dilated cardiomyopathy or fulfulling criteria for the diagnosis of heart failure or hypokinetic non-dilated cardiomyopathy.

Exclusion criteria

✕. New York Heart Association functional class IV.
✕. Patients with a left ventricular assist device or who have had a heart transplant.
✕. Change in heart failure medications within the last month.
✕. CRT implantation within the last 6 months.
✕. Inability to perform exercise due to orthopedic or other non-cardiovascular limitations.
✕. Clinical history of exercise-induced syncope likely caused by ventricular tachyarrhythmias.
✕. Current participation in moderate or high intensity exercise exceeding 2.5 hours/per week.
✕. Inability to give informed consent.

What they're measuring

Difference in change in peak oxygen uptake (VO2peak) as measured in an incremental cycle-ergometer exercise test to exhaustion, in the placebo vs intervention period

Timeframe: 8 weeks

Trial details

NCT IDNCT05180188

SponsorRigshospitalet, Denmark

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-09-21

View on ClinicalTrials.gov More Cardiomyopathies trials